Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. Methods: A retrospective analysis of pulmonary infection and drug-induced interstitial pneumonitis (DIIP) was performed using lymphoma registry data. R-CHOP was administered in 71 patients and CHOP in 29 patients. Results: The severe pulmonary adverse events tended to occur more frequently with R-CHOP (18.3%) than CHOP alone (13.8%), although the difference was not significant (p = 0.771). DIIP occurred in five patients in the R-CHOP arm (7%) and in one in the CHOP arm (3%). The continuous use of steroids for conditions other than lymphoma significantly increased the risk of pulmonary infection including Pneumocystis jiroveci pneumonia (p = 0.036) in the multivariate analysis. International prognostic index, tumor stage, smoking, previous tuberculosis, chronic obstructive pulmonary disease, and lymphoma involvement of lung parenchyma were not related to pulmonary adverse events. Patients who experienced severe pulmonary events showed shorter survival when compared to those without complications (p = 0.002). Conclusions: Our experiences with serial cases with DIIP during chemotherapy and the correlation of continuous steroid use with pulmonary infection suggest that the incidence of pulmonary complications might be high during lymphoma treatment, and careful monitoring should be performed. (Korean J Intern Med 2010;25:86-92)
Abstract
Background/Aims: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. Methods: A retrospective analysis of pulmonary infection and drug-induced interstitial pneumonitis (DIIP) was performed using lymphoma registry data. R-CHOP was administered in 71 patients and CHOP in 29 patients. Results: The severe pulmonary adverse events tended to occur more frequently with R-CHOP (18.3%) than CHOP alone (13.8%), although the difference was not significant (p = 0.771). DIIP occurred in five patients in the R-CHOP arm (7%) and in one in the CHOP arm (3%). The continuous use of steroids for conditions other than lymphoma significantly increased the risk of pulmonary infection including Pneumocystis jiroveci pneumonia (p = 0.036) in the multivariate analysis. International prognostic index, tumor stage, smoking, previous tuberculosis, chronic obstructive pulmonary disease, and lymphoma involvement of lung parenchyma were not related to pulmonary adverse events. Patients who experienced severe pulmonary events showed shorter survival when compared to those without complications (p = 0.002). Conclusions: Our experiences with serial cases with DIIP during chemotherapy and the correlation of continuous steroid use with pulmonary infection suggest that the incidence of pulmonary complications might be high during lymphoma treatment, and careful monitoring should be performed. (Korean J Intern Med 2010;25:86-92)
참고문헌 (19)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Kimby E, "Tolerability and safety of rituximab (MabThera)", Cancer Treat Rev, 31, pp.456~473 (2005)
- Bienvenu J, "Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment", Hematol J, 2, pp.378~384 (2001)
- Kanelli S, "Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis", Leuk Lymphoma, 42, pp.1329~1337 (2001)
- Hainsworth JD, "First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin’s lymphoma: phase II trial", Clin Lymphoma, 4, pp.36~42 (2003)
- Byrd JC, "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)", Blood, 101, pp.6~14 (2003)
- McLaughlin P, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", J Clin Oncol, 16, pp.2825~2833 (1998)
- Burton C, "Interstitial pneumonitis related to rituximab therapy", N Engl J Med, 348, pp.2690~2691 (2003)
- Swords R, "Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)", Am J Hematol, 77, pp.103~104 (2004)
- Leon RJ, "Rituximab-induced acute pulmonary fibrosis", Mayo Clin Proc, 79, pp.949~953 (2004)
- Wagner SA, "Rituximab-induced interstitial lung disease", Am J Hematol, 82, pp.916~919 (2007)
- Ennishi D, "Increased incidence of interstitial pneumonia by CHOP combined with rituximab", Int J Hematol, 87, pp.393~397 (2008)
- Yuna Lee, "Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy", The Korean Journal of Internal Medicine, 21(3), pp.183~186 (2006), 대한내과학회
- Smith MR, "Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance", Oncogene, 22, pp.7359~7368 (2003)
- van der Kolk LE, "Complement activation plays a key role in the side-effects of rituximab treatment", Br J Haematol, 115, pp.807~811 (2001)
- Alho HS, "Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis", Transplantation, 76, pp.516~523 (2003)
- Tonelli AR, "Rituximabinduced hypersensitivity pneumonitis", Respiration, 78, pp.225~229 (2009)
- Czuczman MS, "Rituximab in combination with CHOP or fludarabine in low-grade lymphoma", Semin Oncol, 29, pp.36~40 (2002)
- Voog E, "Neutropenia in patients treated with rituximab", N Engl J Med, 348, pp.2691~2694 (2003)